Sign in

You're signed outSign in or to get full access.

M

Matthew

Complex Branch Manager and Managing Director/Investments at Stifel

St. Louis, MO, US

Matthew MacMichael is a Complex Branch Manager and Managing Director/Investments at Stifel, offering strategic leadership within the Phoenix region. He oversees a broad range of financial advisory services and supports a team engaged across multiple sectors; however, specific companies covered, performance metrics, and quantitative rankings are not publicly disclosed. Matthew has amassed substantial experience at Stifel, advancing to his current senior leadership role and bringing a strong track record in investment management and client service. His credentials likely include FINRA securities licenses and professional registrations in line with his executive responsibilities, reflecting deep regulatory and industry expertise.

Matthew's questions to Karooooo (KARO) leadership

Question · Q3 2026

Matthew asked about the proportion of sales from existing versus new Cartrack customers and requested examples of Cartrack Tag use cases. He also inquired about regulatory or technical issues for Tag rollout in new markets.

Answer

Zak Calisto, Founder and Group CEO, explained that net additions primarily represent new customers, while sales to existing customers typically involve full fleet adoption or new vehicle purchases not reflected in net additions. He described Cartrack Tag's use cases as tracking equipment or vehicles outside the GSM network. He stated that no such issues have been encountered in the markets where they are currently rolling out, though he acknowledged that regulations vary by country.

Ask follow-up questions

Fintool

Fintool can predict Karooooo logo KARO's earnings beat/miss a week before the call

Matthew's questions to KalVista Pharmaceuticals (KALV) leadership

Question · Q3 2025

Matthew (on behalf of Paul Matteis) asked if the multiple cartons per shipment indicated stockpiling behavior among patients due to EKTERLY's convenience and easier storage, and how this behavior might evolve in the future.

Answer

Ben Palleiko (CEO) stated that the company doesn't factually know about stockpiling but noted high self-reported attack rates among current users. He expects usage, refill frequency, and volumes to normalize as EKTERLY's adoption expands to a broader patient population. Nicole Sweeny (Chief Commercial Officer) added that treatment guidelines encourage patients to keep multiple doses on hand.

Ask follow-up questions

Fintool

Fintool can predict KalVista Pharmaceuticals logo KALV's earnings beat/miss a week before the call

Question · Q3 2025

Matthew, on behalf of Paul Matteis, asked for clarification on the multiple cartons per shipment, questioning if it indicates stockpiling behavior among patients and how this trend might evolve in the future.

Answer

Ben Palleiko, Chief Executive Officer, acknowledged that the company does not factually know if stockpiling is occurring but noted that high self-reported attack rates suggest high utilization. He expects usage, refill frequency, and volumes per refill to normalize as EKTERLY expands into the broader patient population. Nicole Sweeney, Chief Commercial Officer, added that treatment guidelines encourage patients to keep enough product on hand for two to three attacks.

Ask follow-up questions

Fintool

Fintool can write a report on KalVista Pharmaceuticals logo KALV's next earnings in your company's style and formatting